药品注册申请号：020357
申请类型：NDA (新药申请)
申请人：EMD SERONO INC
申请人全名：EMD SERONO INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 GLUCOPHAGE METFORMIN HYDROCHLORIDE TABLET;ORAL 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1995/03/03 1995/03/03 Discontinued
002 GLUCOPHAGE METFORMIN HYDROCHLORIDE TABLET;ORAL 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1995/03/03 Discontinued
003 GLUCOPHAGE METFORMIN HYDROCHLORIDE TABLET;ORAL 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1998/11/05 Discontinued
004 GLUCOPHAGE METFORMIN HYDROCHLORIDE TABLET;ORAL 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1998/11/05 Discontinued
005 GLUCOPHAGE METFORMIN HYDROCHLORIDE TABLET;ORAL 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No None 1998/11/05 Discontinued
批准日期，申请提交历史，通知信，药品说明书，审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级；罕用药状态通知信、审评文件、说明书、包装标签备注
2018/05/30 SUPPL-34（补充） Approval Labeling UNKNOWN
2017/04/05 SUPPL-39（补充） Approval Labeling 901 REQUIRED
2017/04/05 SUPPL-37（补充） Approval Labeling STANDARD
2013/11/13 SUPPL-36（补充） Approval Manufacturing (CMC) PRIORITY
2013/03/14 SUPPL-35（补充） Approval Manufacturing (CMC) PRIORITY
2008/08/27 SUPPL-31（补充） Approval Labeling STANDARD
2006/11/01 SUPPL-30（补充） Approval Labeling STANDARD
2004/03/19 SUPPL-27（补充） Approval Labeling STANDARD
2004/03/19 SUPPL-26（补充） Approval Labeling STANDARD
2002/01/08 SUPPL-24（补充） Approval Labeling STANDARD
2001/04/19 SUPPL-20（补充） Approval Efficacy STANDARD
2001/02/08 SUPPL-22（补充） Approval Labeling STANDARD
2000/12/15 SUPPL-19（补充） Approval Efficacy STANDARD
2000/08/04 SUPPL-21（补充） Approval Manufacturing (CMC) PRIORITY
1999/09/22 SUPPL-17（补充） Approval Efficacy STANDARD
1999/06/07 SUPPL-18（补充） Approval Manufacturing (CMC) PRIORITY
1999/06/01 SUPPL-15（补充） Approval Manufacturing (CMC) PRIORITY
1999/03/12 SUPPL-16（补充） Approval Manufacturing (CMC) PRIORITY
1998/12/04 SUPPL-14（补充） Approval Manufacturing (CMC) PRIORITY
1998/11/18 SUPPL-13（补充） Approval Manufacturing (CMC) PRIORITY
1998/11/05 SUPPL-11（补充） Approval Manufacturing (CMC) PRIORITY
1998/10/22 SUPPL-10（补充） Approval Efficacy PRIORITY
1998/07/02 SUPPL-9（补充） Approval Manufacturing (CMC) PRIORITY
1998/05/15 SUPPL-7（补充） Approval Manufacturing (CMC) PRIORITY
1998/02/10 SUPPL-8（补充） Approval Labeling STANDARD
1997/11/06 SUPPL-6（补充） Approval Labeling STANDARD
1997/06/06 SUPPL-5（补充） Approval Manufacturing (CMC) PRIORITY
1996/07/26 SUPPL-4（补充） Approval Manufacturing (CMC) PRIORITY
1996/04/30 SUPPL-3（补充） Approval Manufacturing (CMC) PRIORITY
1995/09/13 SUPPL-2（补充） Approval Manufacturing (CMC) PRIORITY
1995/03/03 ORIG-1（原始申请） Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息（来自FDA橙皮书Orange Book）
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
无
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
无
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
参考引用1
参考引用2
©2006-2024 DrugFuture->U.S. FDA Drugs Database